Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
Nature

Cecum location in rats and the implications for intraperitoneal injections

Intraperitoneal (i.p.) injection is a common route for parenteral administration of drugs in laboratory rodents. The i.p. technique allows for the deposition of substances into the peritoneal cavity, ...

Schizophrenia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Lundbeck, Intra-cellular Therapies, Sumitomo P…

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...
University of California, San Francisco

Why this Little-Known Birth Control Option Deserves More Attention

Self-administered injectable contraceptives, which are progestin-only shots taken at home every three months, have been ...
Medscape

Subcutaneous Anifrolumab Shows Promise in Lupus Treatment

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- ...

Pacira BioSciences: Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences ...